III

Denago Launches Three New eBikes

Retrieved on: 
Tuesday, February 28, 2023
III, Customer success, Travel, City, Bicycle industry, Multimedia, Cruiser, Road, Online shopping, RV, Sex and the City 2

DALLAS, Feb. 28, 2023 /PRNewswire/ -- With their team of bicycle industry veterans and the upcoming release of three new models of their quality electric bikes, start-up Denago electric bike company is a company to keep your eye on. The new models include the Folding Bike 1, a Cruiser in both step thru and top tube frames, and an update to their City 1 model, the City 2. These new models are available at Denago.com and Denago dealers throughout the US.

Key Points: 
  • The next model is the Denago Folding 1; one of the lightest folding bikes for the price on the market.
  • The Denago cruisers come complete with wide padded saddle, high-rise handlebars, 27.5" smooth rolling tires, fenders, and retails for $1,099.
  • "We are here to help you get on the right Denago eBike," Steve Richey, Head of Customer Success states.
  • Denago Electric Bikes was founded in 2022 in Dallas, Texas by a group of bicycle industry veterans who wanted to focus on bringing a quality line of eBikes to the market.

Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies

Retrieved on: 
Tuesday, February 28, 2023
Marketing, Death, Safety, Administration, III, Dyslipidemia, HKEX, Mortality, Hyperlipidemia, Ageing, Cardiovascular disease, Risk, ASCVD, Patient, SSE, Central South University, PCSK9, General Hospital, Report, Incidence, Prevalence, Pharmaceutical industry, Vaccine

: JS002-003 and JS002-006) evaluating the company’s product ongericimab (a recombinant humanized anti-PCSK9 monoclonal antibody, product code: JS002) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, and both studies have met their primary endpoints.

Key Points: 
  • : JS002-003 and JS002-006) evaluating the company’s product ongericimab (a recombinant humanized anti-PCSK9 monoclonal antibody, product code: JS002) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, and both studies have met their primary endpoints.
  • Dyslipidemia, specifically the increase of low-density lipoprotein cholesterol (“LDL-C”), is the most important independent risk factor for atherosclerotic cardiovascular diseases (“ASCVDs”).
  • Ongericimab is a recombinant humanized anti-PCSK9 monoclonal antibody independently developed by Junshi Biosciences.
  • : JS002-003 and JS002-006) of ongericimab have been successfully completed and met their primary endpoints.

National Alliance for Black Business (NABB) and the U.S. Department of Commerce's Minority Business Development Agency (MBDA) Form a Historic Alliance to Develop Black-Owned Businesses

Retrieved on: 
Monday, February 27, 2023
III, United States census, United States Department of Commerce, MOU, National Black Chamber of Commerce, Organization, Left–right political spectrum, Advisory Council, Minority business enterprise, National Alliance, National Negro Business League, Policy, Growth, Minority Business Development Agency, Enterprise software, Japan Tobacco International, U.S. Department of Defense Strategy for Operating in Cyberspace, U.S. Department of Commerce Office of Security, Conference, MBDA, Movement, Minority Enterprise Development Week, NBCC, Commerce, Cummins, NBL, Management, Black

WASHINGTON, Feb. 27, 2023 /PRNewswire/ -- On Wednesday, February 22, 2023, the U.S. Department of Commerce Minority Business Development Agency (MBDA), and the National Alliance for Black Business (NABB) signed a historic MOU during the NABB's first annual National Black Business Policy Conference in Washington, D.C. The NABB was co-founded by the National Business League (NBL) and the National Black Chamber of Commerce (NBCC), which represent a combined 153 years of service to Black businesses and are now collectively working to organize a unified national black economic agenda.

Key Points: 
  • WASHINGTON, Feb. 27, 2023 /PRNewswire/ -- On Wednesday, February 22, 2023, the U.S. Department of Commerce Minority Business Development Agency (MBDA), and the National Alliance for Black Business (NABB) signed a historic MOU during the NABB's first annual National Black Business Policy Conference in Washington, D.C.
  • "This historic agreement between MBDA and the NABB will strengthen our collective mission to create a strong, equitable economy for all minority businesses and entrepreneurs," said Donald R. Cravins, Jr., Under Secretary of the Minority Business Development Agency.
  • "Both MBDA and the NABB have uplifted Black businesses in the decades since they were formed.
  • More than 100 distinguished Black business leaders, organizations, and corporate executives assembled with the Department of Commerce Under Secretary Donald Cravins Jr., Esq.

BITNILE.COM to Launch Early Access to Its Immersive Metaverse Platform At Mobile World Congress Barcelona 2023

Retrieved on: 
Monday, February 27, 2023
Internet, Metaverse, Mobile, Wireless, Technology, Software, Congress, III, Web browser, Networking hardware, NYSE, 3D, Mobile World Congress, NILE, VR, Personal computer, Reward, Tablet, Multimedia, Imagination, IR, Exhibition, Platform, Video game, Online shopping, Cryptocurrency

Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company formerly known as BitNile Holdings, Inc. (“Ault Alliance” or the “Company”) announced it will be participating at Mobile World Congress Barcelona 2023, the world’s largest mobile industry exhibition, in Barcelona, Spain from February 27, 2023 through March 2, 2023.

Key Points: 
  • Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company formerly known as BitNile Holdings, Inc. (“Ault Alliance” or the “Company”) announced it will be participating at Mobile World Congress Barcelona 2023, the world’s largest mobile industry exhibition, in Barcelona, Spain from February 27, 2023 through March 2, 2023.
  • The Company will showcase early access to its latest product, BITNILE.COM, a new metaverse platform designed to revolutionize the way people experience digital worlds, which is launching on March 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230227005421/en/
    A composite view from a world everyone can visit at BITNILE.COM.
  • Milton “Todd” Ault, III, the Company’s Executive Chairman, stated, “We are excited to showcase our innovative product and look forward to sharing the BITNILE.COM experience with everyone at Mobile World Congress Barcelona 2023.

InDex Pharmaceuticals to attend the ECCO 2023 congress

Retrieved on: 
Monday, February 27, 2023
Bella Center Copenhagen, Index, Inflammatory bowel disease, III, Toll-like receptor 9, Ulcerative colitis, ECCO, Exhibition, Pharmaceutical industry

STOCKHOLM, Feb. 27, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.

Key Points: 
  • STOCKHOLM, Feb. 27, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.
  • ECCO is the largest forum for specialists in inflammatory bowel disease globally.
  • InDex Pharmaceuticals will also be present at booth #C3-17 in the exhibition hall at the Bella Center.
  • "ECCO is the largest forum for specialists in inflammatory bowel disease in the world and a very significant industry and healthcare professional event," said Jenny Sundqvist, CEO of InDex Pharmaceuticals.

InDex Pharmaceuticals to attend the ECCO 2023 congress

Retrieved on: 
Monday, February 27, 2023
Bella Center Copenhagen, Index, Inflammatory bowel disease, III, Toll-like receptor 9, Ulcerative colitis, ECCO, Exhibition, Pharmaceutical industry

STOCKHOLM, Feb. 27, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.

Key Points: 
  • STOCKHOLM, Feb. 27, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.
  • ECCO is the largest forum for specialists in inflammatory bowel disease globally.
  • InDex Pharmaceuticals will also be present at booth #C3-17 in the exhibition hall at the Bella Center.
  • "ECCO is the largest forum for specialists in inflammatory bowel disease in the world and a very significant industry and healthcare professional event," said Jenny Sundqvist, CEO of InDex Pharmaceuticals.

ReGen III Provides Corporate Update

Retrieved on: 
Friday, February 24, 2023
UMO, Carbon, Climate change, III, Regen, FSE, National bank, III Corps (South Vietnam), National Bank of Canada, FEED, US, Security (finance)

Vancouver, British Columbia--(Newsfile Corp. - February 24, 2023) - ReGen III Corp. (TSXV: GIII) (OTCQX: ISRJF) (FSE: PN4) ("ReGen III" or the "Company") is pleased to provide a general corporate update and announce the engagement of National Bank Financial Inc.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 24, 2023) - ReGen III Corp. (TSXV: GIII) (OTCQX: ISRJF) (FSE: PN4) ("ReGen III" or the "Company") is pleased to provide a general corporate update and announce the engagement of National Bank Financial Inc.
    Over the past two quarters, ReGen III has been actively advancing on FEL3 (FEED).
  • The Company is continuing to progress all opportunities for project-level financing, including with strategic investors, industry participants and private equity investors.
  • National Bank Financial Inc. will also advise and assist the Company with the evaluation and execution of other strategic opportunities.
  • Greg Clarkes, Chairman & CEO of ReGen III stated, "We look forward to expanding our working relationship with one of Canada's leading investment banks.

InvestmentPitch Media Video Discusses Inflection Resources’ Signing of Non-Binding Heads of Agreement with AngloGold Ashanti for Multi-Year Exploration Earn-In Across Portfolio of Copper-Gold Projects in Australia

Retrieved on: 
Friday, February 24, 2023
AngloGold Ashanti, III, News, Inflection, Gold, Phase II, CSE, Lachlan Fold Belt, Evolution, AUD, Agreement, Star Trek: Phase II, Duck Creek, Mining, Pharmaceutical industry, Northparkes

If these links are not enabled, please visit www.InvestmentPitch.com and enter “Inflection” in the search box.

Key Points: 
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “Inflection” in the search box.
  • Following execution of the Earn-in Agreement, AngloGold shall fund a total of AUD$10 million on exploration expenditures across the portfolio of projects within three years as part of a Phase I exploration program.
  • Alistair Waddell, President and CEO, stated: “The execution of this Heads of Agreement with AngloGold Ashanti is a major milestone for the Company.
  • We fully anticipate recommencing drilling immediately following the execution of the Earn-in Agreement, all of which will now be fully funded by AngloGold.

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Safety, Bristol Myers Squibb, ID, FTI, FLT3, Cancer, QT interval, III, Farnesol, EGFR, IDH, Disease, EORTC, Organization, Research, IND, Webcast, FDA, Investment, Patient, Element, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ASH, KRAS, PI3, CRH, Azacitidine, Renal cell carcinoma, Kura, KURA, Society, AML, HNSCC, Head, CR, PIK3CA, Daunorubicin, Data, Food, G&A, Lung cancer, Acute myeloid leukemia, Pharmaceutical industry, Video game

ET –

Key Points: 
  • ET –
    SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2022 financial results and provided a corporate update.
  • Research and development expenses for the fourth quarter of 2022 were $22.7 million, compared to $21.0 million for the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $12.5 million, compared to $12.1 million for the fourth quarter of 2021.
  • ET / 1:30 p.m. PT today, February 23, 2023, to discuss the financial results for the fourth quarter and full year 2022 and to provide a corporate update.

BITNILE.COM Announces Creation of “NILE” Coin Available Exclusively for In-World Use on BITNILE.COM

Retrieved on: 
Friday, February 24, 2023
Software, Internet, Cryptocurrency, Metaverse, Professional Services, Technology, Digital Cash Management, Digital Assets, Mobile, Wireless, III, Web browser, Networking hardware, NYSE, 3D, Growth, Tablet, Multimedia, Imagination, Platform, Video game

View the full release here: https://www.businesswire.com/news/home/20230224005197/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230224005197/en/
    A composite view from a world everyone can visit at BITNILE.COM.
  • The only limit to what you can see, visit and do at BITNILE.COM is your imagination.
  • BITNILE.COM enables users to participate in the metaverse with unique avatars, customized skins, and digital accessories, all which can be paid for by using the NILE coin.
  • In my opinion BITNILE.COM will grow to be the largest and most profitable asset in the Ault Alliance family of companies.